Anthem Biosciences IPO is generating buzz in the Indian capital markets as one of the year’s most anticipated bookbuilding offerings. With an estimated size of ₹3,395 crores and backed by marquee managers such as JM Financial Limited, Citigroup, J.P. Morgan India, and Nomura, this Contract Research, Development, and Manufacturing Organization (CRDMO) is positioning itself for a high‑profile debut on the BSE and NSE.
What Is the Anthem Biosciences IPO?
Anthem Biosciences IPO is an offer for sale of pre‑issue shares held by promoters and existing shareholders, aggregating up to ₹3,395 crores. Unlike a fresh capital raise, the company itself will not receive proceeds; instead, selling shareholders—promoters Ajay Bhardwaj, Ganesh Sambasivam, K. Ravindra Chandrappa, and Ishaan Bhardwaj—will realize gains after expenses and taxes.
-
Issue Type: Bookbuilding IPO
-
Sale Type: Offer for Sale
-
Face Value: ₹2 per share
-
Listing Venues: BSE & NSE
-
Book‑Running Lead Manager: JM Financial Limited
-
Registrar: KFin Technologies Limited
Key Dates & Subscription Details
While final dates and price bands are “yet to be announced,” here’s a tentative timeline every subscriber should watch closely:
-
IPO Open Date: [To be announced]
-
IPO Close Date: [To be announced]
-
Allotment Finalization: Expected shortly after closing
-
UPI Mandate Cut‑off: 5 PM on the closing day
Reservation Breakdown
-
QIB (Qualified Institutional Buyers): Up to 50%
-
NII (Non‑Institutional Investors): At least 15%
-
Retail Individual Investors: At least 35%
Why Invest in Anthem Biosciences Limited?
Anthem Biosciences is a fully integrated CRDMO, specializing in end‑to‑end services—from discovery and early development to commercial manufacturing of active pharmaceutical ingredients (APIs) and specialty ingredients.
-
Robust Pipeline & Diversified Customer Base
-
196 active projects as of September 30, 2024—spanning discovery, early‑ and late‑phase development, and commercialization.
-
Over 550 customers across 44+ countries, including the U.S., Europe, and Japan.
-
-
Specialized Capabilities
-
Fermentation‑based APIs: Probiotics, enzymes, peptides, vitamin analogues, and biosimilars.
-
Proprietary process patents and 24 pending global applications, underlining a strong innovation focus.
-
-
Strong Financial Metrics (₹ crore, 6 months to Sep 30, 2024)
-
Revenue: 910.85
-
PAT (Profit After Tax): 244.31
-
EBITDA: 327.50
-
ROE & RoNW: ~20%
-
These figures illustrate healthy margins (36.25% EBITDA margin, 24.77% PAT margin) and a conservative debt‑equity ratio (0.12), reflecting sound financial management.
Competitive Strengths
-
One‑Stop Drug Lifecycle Services: From small molecules to biologics, India’s fastest‑growing CRDMO.
-
Innovation‑Driven Model: Deep domain expertise and technological edge.
-
Client‑Centric Approach: Long‑standing partnerships with both emerging biotech firms and global pharma giants.
-
Experienced Leadership: Backed by a qualified team of chemists, biologists, engineers, and non‑clinical researchers.
How to Apply for the Anthem Biosciences IPO
-
Demat & Trading Account: Ensure active accounts with Zerodha, Upstox, or any SEBI‑registered broker.
-
UPI Mandate: Link your bank account for payment authorizations.
-
Bidding Process: Place bids within the announced price band and lot size once the IPO opens.
-
Allotment & Listing: Monitor allotment status via KFin’s online portal and track listing on BSE/NSE.
Conclusion
The Anthem Biosciences IPO presents a compelling opportunity to diversify into the high‑growth CRDMO sector. With a robust order book, a strong innovation pipeline, and solid margins, it appeals to long‑term investors. Prospective subscribers should, however, review the final issue price against peer valuations before placing their bids.
